This release summarizes a meta-analysis of 66 studies on sleep deprivation as a therapy for depression that suggests deprivation had an antidepressant effect roughly half the time. The sleep deprivation varied in length and the precise way it was provided to patients. Partial sleep deprivation, or sleeping for three to four hours, followed by forced wakefulness for 20 to 21 hours appeared equally as effective as total sleep deprivation (being deprived of sleep for 36 hours). The release says that the analysis provided very helpful details on effectiveness in “many populations” but it does not give us any examples of the populations grouped by gender, age or ethnicity that were studied. Most importantly, it doesn’t note that measured benefits were extremely short-term in most patient volunteers who found their gains were reversed after the next full night’s sleep. This key finding wasn’t missed in a Philadelphia Inquirer story on the same study which we also reviewed.
Depression is a major cause of disability in the US and around the world, with estimates that 16.1 million adults in the US had an episode in 2015, according to the National Institute of Mental Health. The most common treatment for depression are anti-depressant drugs which don’t work for everyone and carry many side effects. If sleep deprivation was a practical solution for more patients it could relieve suffering and disability.
But is it practical? It’s counter-intuitive that sleep deprivation can act as a clinical treatment for depression. After all, a hallmark of depression is the inability to sleep. Conversely, many patients with depression start to feel better for the long term when they can start getting a good night’s sleep. It’s also important to note that forced sleep deprivation is known to affect mental and physical health. In the published study, authors noted that the benefit of sleep deprivation is “transient in most individuals and reversed following a subsequent night of sleep.” This does not seem like a durable treatment.
More research is needed, as the authors say in the release.
The release does not mention costs. One may assume there is no cost to sleep deprivation but the release notes that the deprivation in the studies was mostly monitored in inpatient facilities. That has a cost. However, if the intervention is not done in an inpatient facility there would not be a directly attributable cost so we’ll rate this Not Applicable.
The release does not provide any numbers putting the benefits in context. It uses the phrase “roughly half” to describe how many patients benefit from sleep deprivation, but does not provide more numbers. Here is one of the statements about benefit. (Italics added.)
“These studies in our analysis show that sleep deprivation is effective for many populations,” said lead author Elaine Boland, PhD, a clinical associate and research psychologist at the Cpl. Michael J. Crescenz VA Medical Center. “Regardless of how the response was quantified, how the sleep deprivation was delivered, or the type of depression the subject was experiencing, we found a nearly equivalent response rate.”
These statements about effectiveness lack the numbers and nuance needed to make this helpful for readers.
The study itself includes this clarifying statement: “Sleep deprivation can be a useful clinical tool for depressed patients if the effects can be sustained: more research must be done to explore ways of extending the antidepressant effect and/or preventing depressive relapse.” We wish the release had included that information.
The release should also have noted the temporary nature of relief from sleep deprivation and that the inability to sleep well — sleep deprivation — is also a very common symptom of depression.
There are many harms associated with sleep deprivation and these are not mentioned. Johns Hopkins has an info-graphic identifying some of them which include adverse effects on mood, memory and health.
The release provides sufficient details on how this large study of studies was conducted:
“Reviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample. They also explored how response to sleep deprivation may differ across studies according to how “response” is defined in each study.”
The release listed the federal grants and two medical device companies that provided funding for the study. One of the device companies manufactures devices for sleeping and respiratory care. There does not appear to be any direct conflict, but we would have liked a statement saying that.
The release mentions that depression is most typically treated with anti-depressant drugs. We would have liked a little more context for readers on other non-drug treatments such as exercise and cognitive behavioral therapy.
The release does not say whether sleep-deprivation therapy is available as an alternative for most patients. In fact, sleep deprivation is not used as a treatment — only in research studies — and has been for decades.
The release states it is “the first meta-analysis on the subject in nearly 30 years.” This may be true, but there are other peer-reviewed journal articles on sleep deprivation in conjunction with other treatments as a therapy for depression so the idea of using this therapy far from novel.
There was no unjustifiable language.
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
This news release looks at a program to introduce a quality improvement initiative aimed at…
Systematic, Criteria-Driven
We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.
Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.
-Gary Schwitzer, Publisher, HealthNewsReview.org
By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
This news release looks at a program to introduce a quality improvement initiative aimed at…
A guide to specificity, sensitivity, positive predictive value, and other medical testing concepts. https://t.co/wDwTktPiWg @HealthNewsRevu
.@HealthNewsRevu, qui annonce son arrêt en décembre prochain après 12 ans d'activité. Ce site, véritable chien de garde de l'info santé, n'a eu de cesse de lutter contre la mésinformation, la désinformation et les conflits d'intérêt dans le journalisme médico-scientifique.
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
This release from Johns Hopkins reports on a small, preliminary trial that shows adding a…
This news release from the FDA announces the agency’s approval of a new drug, dupilumab…
This news release looks at a program to introduce a quality improvement initiative aimed at…